Antagonists of PD-1 and PD-L1 in Cancer Treatment

The PD-1 pathway, comprising the immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in the tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release the brakes" on anti-tumor immunity and have de...

Full description

Bibliographic Details

Published in:	Seminars in oncology Vol. 42; no. 4; pp. 587 - 600
Main Authors:	Lipson, Evan J, Forde, Patrick M, Hammers, Hans-Joerg, Emens, Leisha A, Taube, Janis M, Topalian, Suzanne L
Format:	Journal Article
Language:	English
Published:	United States 01.08.2015
Subjects:	Antineoplastic Agents - therapeutic use B7-H1 Antigen - antagonists & inhibitors Biomarkers, Tumor - metabolism Humans Immunosuppression - methods Neoplasms - drug therapy Neoplasms - metabolism Programmed Cell Death 1 Receptor - antagonists & inhibitors Tumor Microenvironment - drug effects
ISSN:	1532-8708
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!